Boston Scientific Corporation Can’t Burn Your Long Portfolio. Option Traders are Bullish

 Boston Scientific Corporation Can't Burn Your Long Portfolio. Option Traders are Bullish

In today’s session Boston Scientific Corporation (BSX) registered an unusually high (604) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious BSX increase. With 604 contracts traded and 22564 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: BSX161118C00021000 closed last at: $0.8 or 38.9% down. About 3.26 million shares traded hands. Boston Scientific Corporation (NYSE:BSX) has risen 19.08% since March 29, 2016 and is uptrending. It has outperformed by 15.61% the S&P500.

Boston Scientific Corporation (NYSE:BSX) Ratings Coverage

Out of 22 analysts covering Boston Scientific Corporation (NYSE:BSX), 17 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 77% are positive. $29 is the highest target while $19 is the lowest. The $24.42 average target is 10.40% above today’s ($22.12) stock price. Boston Scientific Corporation has been the topic of 29 analyst reports since July 27, 2015 according to StockzIntelligence Inc. Stifel Nicolaus maintained Boston Scientific Corporation (NYSE:BSX) on Thursday, April 28 with “Buy” rating. Citigroup initiated the shares of BSX in a report on Thursday, November 12 with “Buy” rating. On Monday, May 23 the stock rating was downgraded by BTIG Research to “Neutral”. The rating was maintained by Needham with “Buy” on Friday, July 29. The stock of Boston Scientific Corporation (NYSE:BSX) has “Outperform” rating given on Thursday, April 28 by RBC Capital Markets. The stock of Boston Scientific Corporation (NYSE:BSX) earned “Neutral” rating by Wedbush on Friday, July 29. Benchmark maintained Boston Scientific Corporation (NYSE:BSX) rating on Thursday, July 23. Benchmark has “Buy” rating and $20 price target. FinnCap maintained it with “Corporate” rating and $27 target price in Thursday, October 29 report. The stock has “Buy” rating given by UBS on Tuesday, September 22. On Thursday, April 28 the stock rating was maintained by Wedbush with “Neutral”.

According to Zacks Investment Research, “Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of minimally invasive medical devices. The company’s products are used in a broad range of interventional medical specialties, including cardiology, electrophysiology, gastroenterology, neuro-endovascular therapy, pulmonary medicine, radiology, urology and vascular surgery.”

Insitutional Activity: The institutional sentiment increased to 1.16 in 2016 Q2. Its up 0.23, from 0.93 in 2016Q1. The ratio is positive, as 25 funds sold all Boston Scientific Corporation shares owned while 168 reduced positions. 63 funds bought stakes while 160 increased positions. They now own 1.23 billion shares or 2.15% less from 1.26 billion shares in 2016Q1.
Amer Century Incorporated has 9.07 million shares for 0.24% of their US portfolio. Moreover, Twin Tree Lp has 0.02% invested in Boston Scientific Corporation (NYSE:BSX) for 57,653 shares. Avalon Asset Mngmt owns 50,000 shares or 0.67% of their US portfolio. Mizuho Trust Banking Ltd last reported 2.16 million shares in the company. Deere & last reported 140,262 shares in the company. Fernwood Ltd has 44,774 shares for 1.02% of their US portfolio. Sumitomo Life has 0.37% invested in the company for 114,734 shares. Comerica has 0.17% invested in the company for 10,659 shares. Wetherby Asset Management has 0.07% invested in the company for 13,361 shares. Utah Retirement Systems accumulated 0.15% or 246,605 shares. Moreover, Signaturefd Limited Liability Corp has 0% invested in Boston Scientific Corporation (NYSE:BSX) for 807 shares. The Colorado-based Tributary Mngmt Ltd has invested 0.4% in Boston Scientific Corporation (NYSE:BSX). Dodge & Cox, a California-based fund reported 384,930 shares. Norinchukin Retail Bank The has 0.04% invested in the company for 71,169 shares. Fifth Third Commercial Bank has 9,058 shares for 0% of their US portfolio.

Insider Transactions: Since May 2, 2016, the stock had 0 insider purchases, and 12 sales for $9.76 million net activity. 100,000 shares were sold by Mahoney Michael F, worth $2.27 million. $1.88M worth of Boston Scientific Corporation (NYSE:BSX) shares were sold by Ballinger Kevin J.. Pratt Timothy A. had sold 24,000 shares worth $564,970 on Monday, October 3. Another trade for 35,000 shares valued at $841,050 was sold by Phalen Michael P.. $62,020 worth of Boston Scientific Corporation (NYSE:BSX) was sold by Sorenson John Bradley. Mirviss Jeffrey B. also sold $541,038 worth of Boston Scientific Corporation (NYSE:BSX) shares. On Wednesday, July 20 the insider Pierce David A sold $59,594.

Boston Scientific Corporation is a developer, maker and marketer of medical devices that are used in a range of interventional medical specialties. The company has a market cap of $30.94 billion. The Firm offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions , Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation. It has a 404.46 P/E ratio. It operates in three divisions: Cardiovascular, Rhythm Management and MedSurg.

BSX Company Profile

Boston Scientific Corporation, incorporated on June 22, 1979, is a developer, maker and marketer of medical devices that are used in a range of interventional medical specialties. The Firm offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation. The Firm operates through three divisions: Cardiovascular, Rhythm Management and MedSurg. The Company’s Cardiovascular segment consists of Interventional Cardiology and PI businesses. The Company’s Rhythm Management segment consists of CRM and EP businesses. The Company’s MedSurg segment consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses.

More recent Boston Scientific Corporation (NYSE:BSX) news were published by: Prnewswire.com which released: “Boston Scientific To Participate In 25th Annual Credit Suisse Healthcare …” on October 25, 2016. Also Prnewswire.com published the news titled: “Professor Ian Meredith To Join Boston Scientific As Executive Vice President …” on October 10, 2016. Prnewswire.com‘s news article titled: “Boston Scientific to Webcast Conference Call Discussing Third Quarter 2016 …” with publication date: October 03, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment